<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F601DBFD-0D01-4286-9C28-6950F9BC5955"><gtr:id>F601DBFD-0D01-4286-9C28-6950F9BC5955</gtr:id><gtr:name>Autifony Therapeutics Limited</gtr:name><gtr:address><gtr:line1>B205 IMPERIAL COLLEGE INCUBATOR , LEVEL 1 BESSEMER BUILDING IMPERIAL COLLEGE</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F601DBFD-0D01-4286-9C28-6950F9BC5955" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>F601DBFD-0D01-4286-9C28-6950F9BC5955</gtr:id><gtr:name>Autifony Therapeutics Limited</gtr:name><gtr:address><gtr:line1>B205 IMPERIAL COLLEGE INCUBATOR , LEVEL 1 BESSEMER BUILDING IMPERIAL COLLEGE</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1241270.0</gtr:offerGrant><gtr:projectCost>2068784.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>241171.0</gtr:offerGrant><gtr:projectCost>241171.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/775797B8-1A1B-430A-8852-285B2A2726D6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>775797B8-1A1B-430A-8852-285B2A2726D6</gtr:id><gtr:name>The Victoria University of Manchester</gtr:name><gtr:address><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>443950.0</gtr:offerGrant><gtr:projectCost>443950.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CCDE6CBF-1CF4-458D-A75F-B111BB03AEF3"><gtr:id>CCDE6CBF-1CF4-458D-A75F-B111BB03AEF3</gtr:id><gtr:firstName>Hayley</gtr:firstName><gtr:surname>Reeves</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101443"><gtr:id>8B991D0C-E609-4E12-9508-C9F193E8A9B3</gtr:id><gtr:title>Development of a Kv3 Positive Modulator for the treatment of Schizophrenia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101443</gtr:grantReference><gtr:abstractText>The Autifony-Newcastle-Manchester consortium will develop a new treatment for schizophrenia that targets a novel brain potassium channel, Kv3, that is intimately linked to the emerging understanding of the pathology of the disorder. This first-in-class treatment has the potential to address significant unmet patient need for schizophrenia, a serious psychiatric illness that has seen diminishing investment in research in recent years, despite the huge social and economic burden that it imposes in the UK and across the world. Patients with schizophrenia have a poor quality of life and poor prognosis due to debilitating cognitive and negative symptoms that make work and relationships difficult to sustain. This new drug will treat these symptoms, providing significant improvement over existing medicines and with a lower burden of side effects. Autifony's drug development will be backed up by three leading UK academic groups in the field.</gtr:abstractText><gtr:fund><gtr:end>2015-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1926391</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101443</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>